PASADENA, Calif.--(BUSINESS WIRE)--
Jacobs
Engineering Group Inc. (NYSE:JEC) announced today it was awarded a
contract to expand the Novartis Pharma S.A.S. Biotechnology Center in
Huningue, France.
Under the terms of the agreement, Jacobs is providing engineering,
procurement and construction management (EPCM) services to increase the
site’s production capacity by 70 percent and create a second line of
purification that allows for multiple drugs to be manufactured
simultaneously.
Already one of the world’s largest production facilities for monoclonal
antibodies from mammalian cells, the expansion project adds cell culture
bioreactors to the site.
Jacobs’ services are being led from its operations in Milan, Italy.
In making the announcement, Jacobs Senior Vice President Life Sciences
Robert Norfleet stated, “We look forward to partnering with Novartis on
the expansion of its Huningue site. We’re proud to have this opportunity
to draw on our extensive global EPCM expertise for a project that can
help Novartis improve the lives of people who depend on its treatments.”
The $100 million expansion project is scheduled to be completed in four
years.
Jacobs is one of the world’s largest and most diverse providers of
full-spectrum technical, professional and construction services for
industrial, commercial and government organizations globally. The
company employs 60,000 people and operates in more than 30 countries
around the world. Its Life Sciences business is the largest professional
services provider to the pharmaceutical and biotechnology industries.
For more information, visit www.jacobs.com.
Statements made in this release that are not based on historical fact
are forward-looking statements. We base these forward-looking statements
on management’s current estimates and expectations as well as currently
available competitive, financial and economic data. Forward-looking
statements, however, are inherently uncertain. There are a variety of
factors that could cause business results to differ materially from our
forward-looking statements. For a description of some of the factors
which may occur that could cause actual results to differ from our
forward-looking statements please refer to our 2015 Form 10-K, and in
particular the discussions contained under Items 1 - Business, 1A - Risk
Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and
Analysis of Financial Condition and Results of Operations. We do not
undertake to update any forward-looking statements made herein.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160811005013/en/
Source: Jacobs Engineering Group Inc.